Luminal-like HER2-negative stage IA breast cancer: a multicenter retrospective study on long-term outcome with propensity score analysis

The benefit of adding chemotherapy (CT) to adjuvant hormone therapy (HT) in stage IA luminal-like HER2-negative breast cancer (BC) is unclear. We retrospectively evaluated predictive factors and clinical outcome of 1,222 patients from 4 oncologic centers. Three hundred and eighty patients received C...

Descripción completa

Detalles Bibliográficos
Autores principales: De Angelis, Carmine, Di Maio, Massimo, Crispo, Anna, Giuliano, Mario, Schettini, Francesco, Bonotto, Marta, Gerratana, Lorenzo, Iacono, Donatella, Cinausero, Marika, Riccardi, Ferdinando, Ciancia, Giuseppe, De Laurentiis, Michelino, Puglisi, Fabio, De Placido, Sabino, Arpino, Grazia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5762553/
https://www.ncbi.nlm.nih.gov/pubmed/29348868
http://dx.doi.org/10.18632/oncotarget.22643

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5762553/
https://www.ncbi.nlm.nih.gov/pubmed/29348868
http://dx.doi.org/10.18632/oncotarget.22643

Ejemplares similares